FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

Clinical trial NCT05614739 · RECRUITING

Trial details

NCT number: NCT05614739
Sponsor: Eli Lilly and Company
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Urinary Bladder Neoplasms Neoplasm Metastasis Ureteral Neoplasms

Start date: 2023-01-12
Primary completion: 2027-06-01
Enrollment: 677

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.